The conversion of 2-beta-D-ribofuranosylthiazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties.
D000241:Adenosine / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism* / Q000494:pharmacology; D007168:IMP Dehydrogenase / Q000037:antagonists & inhibitors*; D007658:Ketone Oxidoreductases / Q000037:antagonists & inhibitors*; D007700:Kinetics; D007941:Leukemia P388 / Q000201:enzymology; D008297:Male; D051379:Mice; D009243:NAD / Q000031:analogs & derivatives* / Q000378:metabolism; D012254:Ribavirin / Q000031:analogs & derivatives / Q000378:metabolism*; D012263:Ribonucleosides / Q000378:metabolism*
D000970:Antineoplastic Agents; D012263:Ribonucleosides; D009243:NAD; D012254:Ribavirin; D007168:IMP Dehydrogenase; D007658:Ketone Oxidoreductases; D000241:Adenosine; C033706:tiazofurin